title: IL-1 beta regulates the expression of the Gi2 alpha gene via lipid mediators in guinea pig tracheal muscle.
abstract: When isolated guinea pig muscle preparations were incubated with human recombinant IL-1 beta, mRNA level of Gi2 alpha but not of Gs alpha increased in a time and dose dependent manner. The increase was partially blocked by inhibitors of lipoxygenase (NDGA) and cyclooxygenase (indomethacin) and PAF antagonist (SC47014A), while U46619 (thromboxane A2 mimetic), LTD4, 15-HETE and PAF partially mimicked it. The IL-1 beta induced Gi2 alpha expression was almost completely inhibited by anti-phospholipase A2 antiserum, whereas preimmune serum had no apparent effects. From these observations, we suggest that IL-1 beta first induces the synthesis and release of Type II inflammatory phospholipase A2, which in turn stimulates the expression of Gi2 alpha gene via production of various lipid mediators.
authors.affiliation: Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202.
authors.forename: F
authors.initials: F
authors.lastname: Hirata
authors.forename: J Y
authors.initials: JY
authors.lastname: Lee
authors.forename: T
authors.initials: T
authors.lastname: Sakamoto
authors.forename: A
authors.initials: A
authors.lastname: Nomura
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: A
authors.initials: A
authors.lastname: Hirata
authors.forename: S
authors.initials: S
authors.lastname: Hasegawa
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000818:Animals; D019204:GTP-Binding Proteins / Q000096:biosynthesis*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006168:Guinea Pigs; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology*; D007375:Interleukin-1 / Q000494:pharmacology*; D017998:Leukotriene D4 / Q000494:pharmacology; D008055:Lipids / Q000502:physiology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D009130:Muscle, Smooth / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011450:Prostaglandin Endoperoxides, Synthetic / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology*; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000494:pharmacology; D014132:Trachea / Q000378:metabolism*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D006893:Hydroxyeicosatetraenoic Acids; D007375:Interleukin-1; D008055:Lipids; D016859:Lipoxygenase Inhibitors; D010972:Platelet Activating Factor; D011450:Prostaglandin Endoperoxides, Synthetic; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; D013928:Thromboxane A2; D017998:Leukotriene D4; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D009637:Masoprocol; D019204:GTP-Binding Proteins; D007213:Indomethacin